We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Strong pharmaceutical sales helped Johnson & Johnson (J&J) reach a 3.5 percent increase in fourth quarter earnings, even after the major cost of acquiring Pfizer Consumer Healthcare, the company announced.
Republican members of the House and Senate are proposing a federal commission to study entitlement spending, including Medicare and Medicaid, with an eye toward developing ways to lower the costs of these programs.
An analysis of 84 studies by HHS’ Agency for Healthcare Research and Quality (AHRQ) found no strong evidence that atypical antipsychotics are effective for many of the off-label uses for which they are commonly prescribed.
Strict change-control systems are essential to protect customers from failed drug or biologic products, which makes good business sense for manufacturers.
The public continues to lose trust in the pharma industry, viewing it far differently than the industry perceives itself, according to a new PricewaterhouseCoopers report.
Reintroduction of key legislation presented late last year that would establish a clear and scientifically sound pathway for the approval of follow-on biologics would save the federal government about $14 billion in Medicare costs over the next decade, according to a new report by the Pharmaceutical Care Management Association (PCMA).
Drug companies will increasingly outsource their clinical trials in the coming years, with “many top pharmaceutical companies” expecting to do up to 65 percent of their clinical trials abroad, according to the “Outlook 2007” survey by the Tufts Center for the Study of Drug
Development.
Beginning this month, each issue of The GMP Letter will include a four-page PharmaDevice IT Report supplement. So, in addition to the information on industry best practices and advice on device manufacturing issues you’re used to getting with GMP, you will also receive information on FDA actions on Part 11 and other technology initiatives from the agency and other government offices.